Larotrectinib is an inhibitor of TRK (TRKA, TRKB, TRKC) that binds highly selectively to the protein product encoded by the NTRK fusion gene, blocking the activation and transmission of downstream signaling pathways to inhibit the growth and proliferation of tumor cells with this mutation. The gene discussed is NTRK3; the disease is neoplasm.